Mabpharm (HKSE:02181) FCF Margin % : 183.10% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mabpharm's Free Cash Flow for the six months ended in Dec. 2023 was HK$86.40 Mil. Mabpharm's Revenue for the six months ended in Dec. 2023 was HK$47.19 Mil. Therefore, Mabpharm's FCF Margin % for the quarter that ended in Dec. 2023 was 183.10%.

As of today, Mabpharm's current FCF Yield % is 2.61%.

The historical rank and industry rank for Mabpharm's FCF Margin % or its related term are showing as below:

HKSE:02181' s FCF Margin % Range Over the Past 10 Years
Min: -420.04 Med: -325.5 Max: 44
Current: 44

During the past 7 years, the highest FCF Margin % of Mabpharm was 44.00%. The lowest was -420.04%. And the median was -325.50%.

HKSE:02181's FCF Margin % is ranked better than
96.85% of 1047 companies
in the Biotechnology industry
Industry Median: -145.04 vs HKSE:02181: 44.00

Mabpharm FCF Margin % Historical Data

The historical data trend for Mabpharm's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm FCF Margin % Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-420.04

-325.50

44.00

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial								-10,913.78	-378.22	-269.32	-92.32	183.10

Competitive Comparison of Mabpharm's FCF Margin %

For the Biotechnology subindustry, Mabpharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mabpharm's FCF Margin % falls into.

Mabpharm FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mabpharm's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	41.946	/	95.335
	=	44.00 %

Mabpharm's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	86.399	/	47.187
	=	183.10 %

Mabpharm FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mabpharm's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Mabpharm (HKSE:02181) Headlines

No Headlines